Celecoxib Repurposing in Cancer Therapy: Molecular Mechanisms and Nanomedicine-Based Delivery Technologies

References

• Gunaydin C , BilgeSS. Effects of nonsteroidal anti-inflammatory drugs at the molecular level. Eurasian J. Med.50(2), 116–121 (2018).
   PubMed Web of Science ®Google Scholar
• Tortorella MD , ZhangY, TalleyJ. Desirable properties for 3rd generation cyclooxygenase-2 inhibitors. Mini Rev. Med. Chem.16(16), 1284–1289 (2016).
   PubMed Web of Science ®Google Scholar
• Kismet K , AkayMT, AbbasogluO, ErcanA. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect. Prev.28(2), 127–142 (2004).
   PubMedGoogle Scholar
• Huang C , ChenY, LiuHet al. Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity. Oncotarget8(70), 115254–115269 (2017).
   PubMedGoogle Scholar
• Li J , HaoQ, CaoW, VadgamaJV, WuY. Celecoxib in breast cancer prevention and therapy. Cancer Manag. Res.10, 4653–4667 (2018).
   PubMed Web of Science ®Google Scholar
• Hamy AS , TuryS, WangXet al. Celecoxib with neoadjuvant chemotherapy for breast cancer might worsen outcomes differentially by COX-2 expression and ER status: exploratory analysis of the REMAGUS02 trial. J. Clin. Oncol.37(8), 624–635 (2019).
   PubMed Web of Science ®Google Scholar
• Blanke CD . Celecoxib with chemotherapy in colorectal cancer. Oncology (Williston Park)16(3 Suppl. 4), 17–21 (2002).
   PubMed Web of Science ®Google Scholar
• Guo Q , LiQ, WangJet al. A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: a preliminary, three-center, clinical trial study. Medicine (Baltimore)98(27), e16234–e16234 (2019).
   PubMed Web of Science ®Google Scholar
• Takhar H , SinghalN, MislangAet al. Phase II study of celecoxib with docetaxel chemoradiotherapy followed by consolidation chemotherapy docetaxel plus cisplatin with maintenance celecoxib in inoperable stage III nonsmall cell lung cancer. Asia Pac. J. Clin. Oncol.14(1), 91–100 (2018).
   PubMed Web of Science ®Google Scholar
• Lee R , ChoiYJ, JeongMSet al. Hyaluronic acid-decorated glycol chitosan nanoparticles for pH-sensitive controlled release of doxorubicin and celecoxib in nonsmall cell lung cancer. Bioconjug. Chem.31(3), 923–932 (2020).
   PubMed Web of Science ®Google Scholar
• Dai P , LiJ, MaXP, HuangJ, MengJJ, GongP. Efficacy and safety of COX-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: a meta-analysis. Onco Targets Ther.11, 721–730 (2018).
   PubMed Web of Science ®Google Scholar
• Yusup G , AkutsuY, MutallipMet al. A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma. Int. J. Oncol.44(4), 1146–1152 (2014).
   PubMed Web of Science ®Google Scholar
• Gong L , ThornCF, BertagnolliMM, GrosserT, AltmanRB, KleinTE. Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet. Genomics22(4), 310–318 (2012).
   PubMed Web of Science ®Google Scholar
• Zhang W , YiL, ShenJ, ZhangH, LuoP, ZhangJ. Comparison of the benefits of celecoxib combined with anticancer therapy in advanced non-small cell lung cancer: a meta-analysis. J. Cancer11(7), 1816–1827 (2020).
   PubMed Web of Science ®Google Scholar
• Zhou S , YangS, HuangG. Design, synthesis and bioactivities of celecoxib analogues or derivatives. Bioorg. Med. Chem.25(17), 4887–4893 (2017).
   PubMed Web of Science ®Google Scholar
• Park D , KimY, KimHet al. Hyaluronic acid promotes angiogenesis by inducing RHAMM-TGFβ receptor interaction via CD44-PKCδ. Mol. Cells33(6), 563–574 (2012).
   PubMed Web of Science ®Google Scholar
• Abuzar SM , HyunSM, KimJHet al. Enhancing the solubility and bioavailability of poorly water-soluble drugs using supercritical antisolvent (SAS) process. Int. J. Pharm.538(1–2), 1–13 (2018).
   PubMed Web of Science ®Google Scholar
• Heravi RE , HadizadehF, SankianMet al. Novel selective Cox-2 inhibitors induce apoptosis in Caco-2 colorectal carcinoma cell line. Eur. J. Pharm. Sci.44(4), 479–486 (2011).
   PubMed Web of Science ®Google Scholar
• Wang Z , ChenJ-Q, LiuJ-L. COX-2 Inhibitors and gastric cancer. Gastroenterol. Res. Pract.2014, 132320 (2014).
   PubMed Web of Science ®Google Scholar
• Xia D , WangD, KimS-H, DuBoisRN. Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat. Med.18(2), 224–226 (2012).
   PubMed Web of Science ®Google Scholar
• Chiu C-H , McEnteeMF, WhelanJ. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res.57(19), 4267–4273 (1997).
   PubMed Web of Science ®Google Scholar
• Dubois RN , HylindLM, RobinsonCRet al. Prostaglandin levels in human colorectal mucosa (effects of sulindac in patients with familial adenomatous polyposis). Digest. Dis. Sci.43(2), 311–316 (1998).
   PubMed Web of Science ®Google Scholar
• Zelenay S , VanDer Veen AG, BöttcherJPet al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell162(6), 1257–1270 (2015).
   PubMed Web of Science ®Google Scholar
• Xu S , ZhouW, GeJ, ZhangZ. Prostaglandin E2 receptor EP4 is involved in the cell growth and invasion of prostate cancer via the cAMP- PKA/PI3K- Akt signaling pathway. Mol. Med. Rep.17(3), 4702–4712 (2018).
   PubMed Web of Science ®Google Scholar
• Huang C , ChenY, LiuHet al. Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin E2 and down-regulating the Wnt pathway activity. Oncotarget8(70), 115254 (2017).
   PubMedGoogle Scholar
• Dai Z-J , MaX-B, KangH-Fet al. Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in vitro and in vivo. Cancer Cell Int.12(1), 53 (2012).
   PubMed Web of Science ®Google Scholar
• Yusup G , AkutsuY, MutallipMet al. A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma. Int. J. Oncol.44(4), 1146–1152 (2014).
   PubMed Web of Science ®Google Scholar
• Liu X , YueP, ZhouZ, KhuriFR, SunS-Y. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J. Natl Cancer Inst.96(23), 1769–1780 (2004).
   PubMed Web of Science ®Google Scholar
• Kim B , KimJ, KimYS. Celecoxib induces cell death on non-small cell lung cancer cells through endoplasmic reticulum stress. Anat. Cell Biol.50(4), 293–300 (2017).
   PubMedGoogle Scholar
• Pang R-P , ZhouJ-G, ZengZ-Ret al. Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt/GSK3β/NAG-1 pathway. Cancer Lett.251(2), 268–277 (2007).
   PubMed Web of Science ®Google Scholar
• Piazza GA , ThompsonWJ, PamukcuRet al. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res.61(10), 3961–3968 (2001).
   PubMed Web of Science ®Google Scholar
• Tinsley HN , GaryBD, KeetonABet al. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol. Cancer Ther.8(12), 3331–3340 (2009).
   PubMed Web of Science ®Google Scholar
• Tinsley HN , GaryBD, ThaiparambilJet al. Colon tumor cell growth–inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev. Res.3(10), 1303–1313 (2010).
   PubMed Web of Science ®Google Scholar
• Soh JW , KaziJU, LiH, ThompsonWJ, WeinsteinIB. Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Mol. Carcinog.47(7), 519–525 (2008).
   PubMed Web of Science ®Google Scholar
• Wang H , YangY-B, ShenH-M, GuJ, LiT, LiX-M. ABT-737 induces Bim expression via JNK signaling pathway and its effect on the radiation sensitivity of HeLa cells. PLoS ONE7(12), (2012).
   Web of Science ®Google Scholar
• Houseknecht KL , ColeBM, SteelePJ. Peroxisome proliferator-activated receptor gamma (PPAR-γ) and its ligands: a review. Domest. Anim. Endocrinol.22(1), 1–23 (2002).
   PubMed Web of Science ®Google Scholar
• Knopfová L , ŠmardaJ. The use of Cox-2 and PPAR-γ signaling in anti-cancer therapies. Exp. Ther. Med.1(2), 257–264 (2010).
   PubMed Web of Science ®Google Scholar
• Gupta RA , TanJ, KrauseWFet al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer. Proc. Natl Acad. Sci. USA97(24), 13275–13280 (2000).
   PubMed Web of Science ®Google Scholar
• Hatae T . Wada M, Yokoyama C, Shimonishi M, Tanabe T. Prostacyclin-dependent apoptosis mediated by PPAR δ. J. Biol. Chem.276, 46260–46267 (2001).
   PubMed Web of Science ®Google Scholar
• He T-C , ChanTA, VogelsteinB, KinzlerKW. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell99(3), 335–345 (1999).
   PubMed Web of Science ®Google Scholar
• Liou J-Y , GhelaniD, YehS, WuKK. Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3ε. Cancer Res.67(7), 3185–3191 (2007).
   PubMed Web of Science ®Google Scholar
• Li LT , JiangG, ChenQ, ZhengJN. Ki67 is a promising molecular target in the diagnosis of cancer. Mol. Med. Rep.11(3), 1566–1572 (2015).
   PubMed Web of Science ®Google Scholar
• Huang J , PowellWC, KhodavirdiACet al. Prostatic intraepithelial neoplasia in mice with conditional disruption of the retinoid X receptor α allele in the prostate epithelium. Cancer Res.62(16), 4812–4819 (2002).
   PubMed Web of Science ®Google Scholar
• Brown JR , DuBoisRN. COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol.23(12), 2840–2855 (2005).
   PubMed Web of Science ®Google Scholar
• Zhou H , LiuW, SuYet al. NSAID sulindac and its analog bind RXR-α and inhibit RXR-α-dependent AKT signaling. Cancer Cell17(6), 560–573 (2010).
   PubMed Web of Science ®Google Scholar
• Dawson MI , ZhangX. Discovery and design of retinoic acid receptor and retinoid X receptor class- and subtype-selective synthetic analogs of all-trans-retinoic acid and 9-cis-retinoic acid. Curr. Med. Chem.9(6), 623–637 (2002).
   PubMed Web of Science ®Google Scholar
• Gupta SC , SundaramC, ReuterS, AggarwalBB. Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim. Biophys. Acta1799(10–12), 775–787 (2010).
   PubMed Web of Science ®Google Scholar
• Takada Y , BhardwajA, PotdarP, AggarwalBB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-κ B activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene23(57), 9247–9258 (2004).
   PubMed Web of Science ®Google Scholar
• Wang G , LiJ, ZhangL, HuangS, ZhaoX, ZhaoX. Celecoxib induced apoptosis against different breast cancer cell lines by down-regulated NF-κB pathway. Biochem. Biophys. Res. Commun.490(3), 969–976 (2017).
   PubMed Web of Science ®Google Scholar
• Yamamoto Y . Yin MJ, Lin KM, Gaynor RB. Sulindac inhibits activation of the NF-kappaB pathway. J. Biol. Chem.274, 27307–27314 (1999).
   PubMed Web of Science ®Google Scholar
• Shishodia S , AggarwalBB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-κB by suppressing activation of I-κB α kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Cancer Res.64(14), 5004–5012 (2004).
   PubMed Web of Science ®Google Scholar
• Kim S-H , SongS-H, KimS-Get al. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-κB as a possible target. J. Cancer Res. Clin. Oncol.130(9), 551–560 (2004).
   PubMed Web of Science ®Google Scholar
• AbdulHameed MDM , HamzaA, ZhanC-G. Microscopic modes and free energies of 3-phosphoinositide-dependent kinase-1 (PDK1) binding with celecoxib and other inhibitors. J. Phys. Chem. B110(51), 26365–26374 (2006).
   PubMed Web of Science ®Google Scholar
• Kulp SK , YangY-T, HungC-Cet al. 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res.64(4), 1444–1451 (2004).
   PubMed Web of Science ®Google Scholar
• Zhu J , HuangJ-W, TsengP-Het al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res.64(12), 4309–4318 (2004).
   PubMed Web of Science ®Google Scholar
• Wei Y , HanX, ZhaoC. PDK1 regulates the survival of the developing cortical interneurons. Molecular brain13, 1–14 (2020).
   PubMed Web of Science ®Google Scholar
• Hanada M , FengJ, HemmingsBA. Structure, regulation and function of PKB/AKT — a major therapeutic target. Biochim. Biophys. Acta1697(1–2), 3–16 (2004).
   PubMed Web of Science ®Google Scholar
• Arico S , PattingreS, BauvyCet al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J. Biol. Chem.277(31), 27613–27621 (2002).
   PubMed Web of Science ®Google Scholar
• Sinicrope FA , HalfE, MorrisJSet al. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol. Biomarkers Prev.13(6), 920–927 (2004).
   PubMed Web of Science ®Google Scholar
• Bundscherer A , VogtT, KoehlG, LandthalerM, HafnerC. Antiproliferative effects of rapamycin and celecoxib in angiosarcoma cell lines. Anticancer Res.30(10), 4017–4023 (2010).
   PubMed Web of Science ®Google Scholar
• Mao JT , RothMD, FishbeinMCet al. Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev. Res.4(7), 984–993 (2011).
   PubMed Web of Science ®Google Scholar
• Oshima M , MuraiN, KargmanSet al. Chemoprevention of intestinal polyposis in the ApcΔ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res.61(4), 1733–1740 (2001).
   PubMed Web of Science ®Google Scholar
• Setiawati A . Celecoxib, a COX-2 selective inhibitor, induces cell cycle arrest at the G2/M phase in HeLa cervical cancer cells. Asia Pac. J. Cancer Prev.17(4), 1655–1659 (2016).
   PubMedGoogle Scholar
• Kunte DP , WaliRK, KoetsierJL, RoyHK. Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase. Mol. Cancer Ther.7(7), 1797–1806 (2008).
   PubMed Web of Science ®Google Scholar
• Kardosh A , BlumenthalM, WangWJ, ChenTC, SchonthalAH. Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer Biol. Ther.3(1), 55–62 (2004).
   PubMed Web of Science ®Google Scholar
• Narayanan BA , CondonMS, BoslandMC, NarayananNK, ReddyBS. Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism (s). Clin. Cancer Res.9(9), 3503–3513 (2003).
   PubMed Web of Science ®Google Scholar
• Liang J , SlingerlandJM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle2, 339–345 (2003).
   PubMed Web of Science ®Google Scholar
• Viglietto G , MottiML, BruniPet al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat. Med.8(10), 1136–1144 (2002).
   PubMed Web of Science ®Google Scholar
• Gurpinar E , GrizzleWE, PiazzaGA. COX-independent mechanisms of cancer chemoprevention by anti-inflammatory drugs. Front. Oncol.3, 181 (2013).
   PubMedGoogle Scholar
• Brown J , Von RoennJ, O’ReganRet al. A phase II study of the proteasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC). J. Clin. Oncol.22(Suppl. 14), 546–546 (2004).
   Google Scholar
• Regulski M , RegulskaK, PrukałaW, PiotrowskaH, StaniszB, MuriasM. COX-2 inhibitors: a novel strategy in the management of breast cancer. Drug Discov. Today21(4), 598–615 (2016).
   PubMed Web of Science ®Google Scholar
• Galon J , CostesA, Sanchez-CaboFet al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science313(5795), 1960–1964 (2006).
   PubMed Web of Science ®Google Scholar
• Sui W , ZhangY, WangZet al. Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H22 murine hepatocarcinoma model. Oncol. Rep.31(5), 2252–2260 (2014).
   PubMed Web of Science ®Google Scholar
• Elwich-Flis S , Sołtysiak-PawluczukD, SpławińskiJ. Anti-angiogenic and apoptotic effects of metabolites of sulindac on chick embryo chorioallantoic membrane. Hybrid. Hybridomics22(1), 55–60 (2003).
   PubMedGoogle Scholar
• Rosas C , SinningM, FerreiraA, FuenzalidaM, LemusD. Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy. Biol. Res.47(1), 27 (2014).
   PubMedGoogle Scholar
• Xu K , WangL, ShuH-KG. COX-2 overexpression increases malignant potential of human glioma cells through Id1. Oncotarget5(5), 1241–1252 (2014).
   PubMedGoogle Scholar
• Kwon IK , SchoenleinPV, DelkJet al. Expression of cyclic guanosine monophosphate-dependent protein kinase in metastatic colon carcinoma cells blocks tumor angiogenesis. Cancer112(7), 1462–1470 (2008).
   PubMed Web of Science ®Google Scholar
• Wei D , WangL, HeY, XiongHQ, AbbruzzeseJL, XieK. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res.64(6), 2030–2038 (2004).
   PubMed Web of Science ®Google Scholar
• Abdelrahim M , SafeS. Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol. Pharmacol.68(2), 317–329 (2005).
   PubMed Web of Science ®Google Scholar
• Lin H-P , KulpSK, TsengP-Het al. Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. Mol. Cancer Ther.3(12), 1671–1680 (2004).
   PubMed Web of Science ®Google Scholar
• Virrey JJ , LiuZ, ChoH-Yet al. Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature. Mol. Cancer Ther.9(3), 631–641 (2010).
   PubMed Web of Science ®Google Scholar
• Niederberger E , ManderscheidC, GröschS, SchmidtH, EhnertC, GeisslingerG. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem. Pharmacol.68(2), 341–350 (2004).
   PubMed Web of Science ®Google Scholar
• Wang L , ChenW, XieX, HeY, BaiX. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer. Exp. Oncol.30(1), 42–51 (2008).
   PubMedGoogle Scholar
• Ghanghas P , JainS, RanaC, SanyalSN. Chemoprevention of colon cancer through inhibition of angiogenesis and induction of apoptosis by nonsteroidal anti-inflammatory drugs. J. Environ. Pathol. Toxicol. Oncol.35(3), 273–289 (2016).
   PubMed Web of Science ®Google Scholar
• Gungor H , IlhanN, EroksuzH. The effectiveness of cyclooxygenase-2 inhibitors and evaluation of angiogenesis in the model of experimental colorectal cancer. Biomed. Pharmacother.102, 221–229 (2018).
   PubMed Web of Science ®Google Scholar
• Zuo C , HongY, QiuXet al. Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3/NF-kB and L1CAM activities. Pancreatol.18(3), 328–333 (2018).
   PubMed Web of Science ®Google Scholar
• Mizushima N . Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature451, 1069–1075 (2008).
   PubMed Web of Science ®Google Scholar
• White E . Deconvoluting the context-dependent role for autophagy in cancer. Nat. Rev. Cancer12(6), 401–410 (2012).
   PubMed Web of Science ®Google Scholar
• Lu Y , LiuL-L, LiuS-Set al. Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells. J. Transl. Med.14(1), 270 (2016).
   PubMedGoogle Scholar
• Liu M , LiC-M, ChenZ-Fet al. Celecoxib regulates apoptosis and autophagy via the PI3K/Akt signaling pathway in SGC-7901 gastric cancer cells. Int. J. Mol. Med.33(6), 1451–1458 (2014).
   PubMed Web of Science ®Google Scholar
• Gao M , YehPY, LuY-Set al. OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma. Cancer Res.68(22), 9348–9357 (2008).
   PubMed Web of Science ®Google Scholar
• Huang S , SinicropeF. Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy6(2), 256–269 (2010).
   PubMed Web of Science ®Google Scholar
• Yu C , LiWB, LiuJB, LuJW, FengJF. Autophagy: novel applications of nonsteroidal anti-inflammatory drugs for primary cancer. Cancer Med.7(2), 471–484 (2018).
   PubMed Web of Science ®Google Scholar
• Siddiqa AJ , ChaudhuryK, AdhikariB. Letrozole dispersed on poly (vinyl alcohol) anchored maleic anhydride grafted low density polyethylene: a controlled drug delivery system for treatment of breast cancer. Colloids Surf. B Biointerfaces116, 169–175 (2014).
   PubMed Web of Science ®Google Scholar
• Seedher N , BhatiaS. Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech4(3), E33 (2003).
   PubMedGoogle Scholar
• Qandil AM , ElMohtadi FH, TashtoushBM. Chemical and in vitro enzymatic stability of newly synthesized celecoxib lipophilic and hydrophilic amides. Int. J. Pharm.416(1), 85–96 (2011).
   PubMedGoogle Scholar
• He J , HanY, XuGet al. Preparation and evaluation of celecoxib nanosuspensions for bioavailability enhancement. RSC Adv.7(22), 13053–13064 (2017).
   Web of Science ®Google Scholar
• Paulson WD , RamSJ, WorkJ. Access blood flow: debate continues. Semin. Dial.14(6), 459–460 (2001).
   PubMedGoogle Scholar
• Dolenc A , KristlJ, BaumgartnerS, PlaninsekO. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int. J. Pharm.376(1–2), 204–212 (2009).
   PubMedGoogle Scholar
• He X , BaroneMR, MarsacPJ, SperryDC. Development of a rapidly dispersing tablet of a poorly wettable compound: formulation DOE and mechanistic study of effect of formulation excipients on wetting of celecoxib. Int. J. Pharm.353(1–2), 176–186 (2008).
   PubMedGoogle Scholar
• Soppimath KS , AminabhaviTM, KulkarniAR, RudzinskiWE. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Rel.70(1–2), 1–20 (2001).
   PubMed Web of Science ®Google Scholar
• Li J , BurgessDJ. Nanomedicine-based drug delivery towards tumor biological and immunological microenvironment. Acta Pharm. Sin. B10(11), 2110–2124 (2020).
   PubMed Web of Science ®Google Scholar
• He W , XingX, WangXet al. Nanocarrier-mediated cytosolic delivery of biopharmaceuticals. Adv. Funct. Mater.30(37), 1910566 (2020).
   Web of Science ®Google Scholar
• Matbou Riahi M , SahebkarA, SadriK, Nikoofal-SahlabadiS, JaafariMR. Stable and sustained release liposomal formulations of celecoxib: in vitro and in vivo anti-tumor evaluation. Int. J. Pharm.540(1–2), 89–97 (2018).
   PubMedGoogle Scholar
• Perumal V , BanerjeeS, DasS, SenRK, MandalM. Effect of liposomal celecoxib on proliferation of colon cancer cell and inhibition of DMBA-induced tumor in rat model. Cancer Nanotechnol.2(1–6), 67–79 (2011).
   PubMedGoogle Scholar
• Ahmed KS , ChanglingS, ShanX, MaoJ, QiuL, ChenJ. Liposome-based codelivery of celecoxib and doxorubicin hydrochloride as a synergistic dual-drug delivery system for enhancing the anticancer effect. J. Liposome Res.30(3), 285–296 (2020).
   PubMed Web of Science ®Google Scholar
• Singh S . Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells. Int. J. Nanomed.13( T-NANO 2014 Abstracts), 11–13 (2018).
   PubMedGoogle Scholar
• Gowda R , KardosG, SharmaA, SinghS, RobertsonGP. Nanoparticle-based celecoxib and plumbagin for the synergistic treatment of melanoma. Mol. Cancer Ther.16(3), 440–452 (2017).
   PubMed Web of Science ®Google Scholar
• Alajami H , FouadE, AshourA, ElbadawyA, KumarA, YassinA. Loading celecoxib into solid lipid nanoparticles significantly enhanced the anticancer activity. Presented at: 45th Controlled Release Society (CRS) Annual Meeting.NY, USA, (22–24 July 2018).
   Google Scholar
• Üner M , YenerG, ErgüvenM. Design of colloidal drug carriers of celecoxib for use in treatment of breast cancer and leukemia. Mater. Sci. Eng. C Mater. Biol. Appl.103, 109874 (2019).
   PubMed Web of Science ®Google Scholar
• Patlolla RR , ChouguleM, PatelAR, JacksonT, TataPN, SinghM. Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J. Control. Rel.144(2), 233–241 (2010).
   PubMed Web of Science ®Google Scholar
• Emami J , PourmashhadiA, SadeghiH, VarshosazJ, HamishehkarH. Formulation and optimization of celecoxib-loaded PLGA nanoparticles by the Taguchi design and their in vitro cytotoxicity for lung cancer therapy. Pharm. Dev. Technol.20(7), 791–800 (2015).
   PubMed Web of Science ®Google Scholar
• Vera M , BarciaE, NegroSet al. New celecoxib multiparticulate systems to improve glioblastoma treatment. Int. J. Pharm.473(1–2), 518–527 (2014).
   PubMedGoogle Scholar
• Said-Elbahr R , NasrM, AlhnanMA, TahaI, SammourO. Nebulizable colloidal nanoparticles co-encapsulating a COX-2 inhibitor and a herbal compound for treatment of lung cancer. Eur. J. Pharm. Biopharm.103, 1–12 (2016).
   PubMed Web of Science ®Google Scholar
• Zhang S , GuoN, WanGet al. pH and redox dual-responsive nanoparticles based on disulfide-containing poly(β-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer. J. Nanobiotechnol.17(1), 109 (2019).
   PubMed Web of Science ®Google Scholar
• Yu R-Y , XingL, CuiP-Fet al. Regulating the Golgi apparatus by co-delivery of a COX-2 inhibitor and Brefeldin A for suppression of tumor metastasis. Biomater. Sci.6(8), 2144–2155 (2018).
   PubMed Web of Science ®Google Scholar
• Chandel D , UppalS, MehtaSK, ShuklaG. Preparation and characterization of celecoxib entrapped guar gum nanoparticles targeted for oral drug delivery against colon cancer: an in-vitro study. J. Drug Deliv. Ther.10(2-s), 14–21 (2020).
   Google Scholar
• Huang J , XuY, XiaoHet al. Core-shell distinct nanodrug showing on-demand sequential drug release to act on multiple cell types for synergistic anticancer therapy. ACS Nano13(6), 7036–7049 (2019).
   PubMed Web of Science ®Google Scholar
• Uram Ł , MisiorekM, PichlaMet al. The effect of biotinylated PAMAM G3 Dendrimers conjugated with COX-2 Inhibitor (celecoxib) and PPAR-γ agonist (Fmoc-L-leucine) on human normal fibroblasts, immortalized keratinocytes and glioma cells in vitro. Molecules24(20), 3801 (2019).
   PubMed Web of Science ®Google Scholar
• Uram Ł , FilipowiczA, MisiorekMet al. Biotinylated PAMAM G3 dendrimer conjugated with celecoxib and/or Fmoc-L-leucine and its cytotoxicity for normal and cancer human cell lines. Eur. J. Pharm. Biopharm.124, 1–9 (2018).
   PubMedGoogle Scholar
• Xv L , QianX, WangYet al. Structural modification of nanomicelles through phosphatidylcholine: the enhanced drug-loading capacity and anticancer activity of celecoxib-casein nanoparticles for the intravenous delivery of celecoxib. Nanomaterials (Basel)10(3), 451 (2020).
   PubMedGoogle Scholar
• Shi L , XuL, WuCet al. Celecoxib-induced self-assembly of smart albumin-doxorubicin conjugate for enhanced cancer therapy. ACS Appl. Mater. Interfaces10(10), 8555–8565 (2018).
   PubMed Web of Science ®Google Scholar
• Abdelmoneem MA , MahmoudM, ZakyAet al. Decorating protein nanospheres with lactoferrin enhances oral COX-2 inhibitor/herbal therapy of hepatocellular carcinoma. Nanomedicine (Lond.)13(19), 2377–2395 (2018).
   PubMed Web of Science ®Google Scholar
• AbdElhamid AS , ZayedDG, HelmyMWet al. Lactoferrin-tagged quantum dots-based theranostic nanocapsules for combined COX-2 inhibitor/herbal therapy of breast cancer. Nanomedicine (Lond.)13(20), 2637–2656 (2018).
   PubMed Web of Science ®Google Scholar
• AbdElhamid AS , HelmyMW, EbrahimSMet al. Layer-by-layer gelatin/chondroitin quantum dots-based nanotheranostics: combined rapamycin/celecoxib delivery and cancer imaging. Nanomedicine (Lond.)13(14), 1707–1730 (2018).
   PubMed Web of Science ®Google Scholar
• Elzoghby AO , MostafaSK, HelmyMW, ElDemellawyMA, SheweitaSA. Superiority of aromatase inhibitor and cyclooxygenase-2 inhibitor combined delivery: hyaluronate-targeted versus PEGylated protamine nanocapsules for breast cancer therapy. Int. J. Pharm.529(1–2), 178–192 (2017).
   PubMed Web of Science ®Google Scholar
• Elzoghby AO , MostafaSK, HelmyMW, ElDemellawyMA, SheweitaSA. Multi-reservoir phospholipid shell encapsulating protamine nanocapsules for co-delivery of letrozole and celecoxib in breast cancer therapy. Pharm. Res.34(9), 1956–1969 (2017).
   PubMed Web of Science ®Google Scholar
• Liu J , ChangB, LiQet al. Redox-responsive dual drug delivery nanosystem suppresses cancer repopulation by abrogating doxorubicin-promoted cancer stemness, metastasis, and drug resistance. Adv. Sci.6(7), 1801987 (2019).
   Web of Science ®Google Scholar
• Zhu W , ZhaoQ, ZhengXet al. Mesoporous carbon as a carrier for celecoxib: the improved inhibition effect on MDA-MB-231 cells migration and invasion. Asian J. Pharm. Sci.9(2), 82–91 (2014).
   Google Scholar
• Wu Y , GuW, TangJ, XuZP. Devising new lipid-coated calcium phosphate/carbonate hybrid nanoparticles for controlled release in endosomes for efficient gene delivery. J. Mater. Chem. B5(34), 7194–7203 (2017).
   PubMed Web of Science ®Google Scholar
• Venkatesan P , PuvvadaN, DashRet al. The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer. Biomaterials32(15), 3794–3806 (2011).
   PubMed Web of Science ®Google Scholar
• Mardani S , MaghsoodiM, GhanbarzadehS, NokhodchiA, YaqoubiS, HamishehkarH. Preparation and characterization of Celecoxib agglomerated nanocrystals and dry powder inhalation formulations to improve its aerosolization performance. Pharm. Sci.23(4), 278–284 (2017).
   Google Scholar
• Jia L , GarzaM, WongHet al. Pharmacokinetic comparison of intravenous carbendazim and remote loaded carbendazim liposomes in nude mice. J. Pharm. Biomed. Anal.28(1), 65–72 (2002).
   PubMed Web of Science ®Google Scholar
• Malam Y , LoizidouM, SeifalianAM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci.30(11), 592–599 (2009).
   PubMed Web of Science ®Google Scholar
• Sahoo SK , LabhasetwarV. Nanotech approaches to drug delivery and imaging. Drug Discov. Today8(24), 1112–1120 (2003).
   PubMed Web of Science ®Google Scholar
• Torchilin V . Antibody-modified liposomes for cancer chemotherapy. Expert Opin. Drug Deliv.5(9), 1003–1025 (2008).
   PubMed Web of Science ®Google Scholar
• Sercombe L , VeeratiT, MoheimaniF, WuSY, SoodAK, HuaS. Advances and challenges of liposome assisted drug delivery. Front. Pharmacol.6, 286 (2015).
   PubMed Web of Science ®Google Scholar
• Olusanya TOB , HajAhmad RR, IbegbuDM, SmithJR, ElkordyAA. Liposomal drug delivery systems and anticancer drugs. Molecules23(4), 907 (2018).
   PubMed Web of Science ®Google Scholar
• Muller RH , MaderK, GohlaS. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur. J. Pharm. Biopharm.50(1), 161–177 (2000).
   PubMed Web of Science ®Google Scholar
• Rajabi M , MousaSA. Lipid nanoparticles and their application in nanomedicine. Curr. Pharm. Biotechnol.17(8), 662–672 (2016).
   PubMed Web of Science ®Google Scholar
• Pardeike J , HommossA, MullerRH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int. J. Pharm.366(1–2), 170–184 (2009).
   PubMed Web of Science ®Google Scholar
• Muller RH , PetersenRD, HommossA, PardeikeJ. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv. Drug Deliv. Rev.59(6), 522–530 (2007).
   PubMed Web of Science ®Google Scholar
• Iqbal MA , MdS, SahniJK, BabootaS, DangS, AliJ. Nanostructured lipid carriers system: recent advances in drug delivery. J. Drug Target.20(10), 813–830 (2012).
   PubMed Web of Science ®Google Scholar
• Duncan R . The dawning era of polymer therapeutics. Nat. Rev. Drug Discov.2(5), 347–360 (2003).
   PubMed Web of Science ®Google Scholar
• Dwivedi N , ShahJ, MishraVet al. Dendrimer-mediated approaches for the treatment of brain tumor. J. Biomater. Sci. Polym. Ed.27(7), 557–580 (2016).
   PubMed Web of Science ®Google Scholar
• Florendo M , FigaczA, SrinageshwarBet al. Use of polyamidoamine dendrimers in brain diseases. Molecules23(9), 2238 (2018).
   PubMed Web of Science ®Google Scholar
• Al-Saidan SM , KrishnaiahYS, PatroSS, SatyanaryanaV. In vitro and in vivo evaluation of guar gum matrix tablets for oral controlled release of water-soluble diltiazem hydrochloride. AAPS PharmSciTech6(1), E14–21 (2005).
   PubMed Web of Science ®Google Scholar
• Sinha VR , MittalBR, BhutaniKK, KumriaR. Colonic drug delivery of 5-fluorouracil: an in vitro evaluation. Int. J. Pharm.269(1), 101–108 (2004).
   PubMed Web of Science ®Google Scholar
• Mudgil D , BarakS, PatelA, ShahN. Partially hydrolyzed guar gum as a potential prebiotic source. Int. J. Biol. Macromol.112, 207–210 (2018).
   PubMed Web of Science ®Google Scholar
• Lohcharoenkal W , WangL, ChenYC, RojanasakulY. Protein nanoparticles as drug delivery carriers for cancer therapy. BioMed Res. Int.2014, 180549 (2014).
   PubMed Web of Science ®Google Scholar
• Kondapi AK . Targeting cancer with lactoferrin nanoparticles: recent advances. Nanomedicine (Lond.)15(21), 2071–2083 (2020).
   PubMed Web of Science ®Google Scholar
• Elzoghby AO , MostafaSK, HelmyMW, ElDemellawyMA, SheweitaSA. Superiority of aromatase inhibitor and cyclooxygenase-2 inhibitor combined delivery: hyaluronate-targeted versus PEGylated protamine nanocapsules for breast cancer therapy. Int. J. Pharm.529(1), 178–192 (2017).
   PubMedGoogle Scholar
• Wong KH , LuA, ChenX, YangZ. Natural ingredient-based polymeric nanoparticles for cancer treatment. Molecules25(16), 3620 (2020).
   PubMed Web of Science ®Google Scholar
• Mateus AY , BarriasCC, RibeiroC, FerrazMP, MonteiroFJ. Comparative study of nanohydroxyapatite microspheres for medical applications. J. Biomed. Mater. Res. A86(2), 483–493 (2008).
   PubMedGoogle Scholar
• Zhang S , GonsalvesKE. Preparation and characterization of thermally stable nanohydroxyapatite. J. Mater. Sci. Mater. Med.8(1), 25–28 (1997).
   PubMed Web of Science ®Google Scholar
• Guggi D , LangothN, HofferMH, WirthM, Bernkop-SchnurchA. Comparative evaluation of cytotoxicity of a glucosamine-TBA conjugate and a chitosan-TBA conjugate. Int. J. Pharm.278(2), 353–360 (2004).
   PubMed Web of Science ®Google Scholar
• Krisanapiboon A , BuranapanitkitB, OungbhoK. Biocompatability of hydroxyapatite composite as a local drug delivery system. J. Orthop. Surg. (Hong Kong)14(3), 315–318 (2006).
   PubMedGoogle Scholar
• Rosenholm JM , MamaevaV, SahlgrenC, LindénM. Nanoparticles in targeted cancer therapy: mesoporous silica nanoparticles entering preclinical development stage. Nanomedicine (Lond.)7(1), 111–120 (2012).
   PubMed Web of Science ®Google Scholar
• She X , ChenL, YiZet al. Tailored mesoporous silica nanoparticles for controlled drug delivery: platform fabrication, targeted delivery, and computational design and analysis. Mini Rev. Med. Chem.18(11), 976–989 (2018).
   PubMed Web of Science ®Google Scholar
• Farooq MA , JabeenA, WangB. Formulation, optimization, and characterization of whey protein isolate nanocrystals for celecoxib delivery. J. Microencapsul. doi: 10.1080/02652048.2021.1915398 (2021) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Jarvis M , KrishnanV, MitragotriS. Nanocrystals: a perspective on translational research and clinical studies. Bioeng. Transl. Med.4(1), 5–16 (2019).
   PubMed Web of Science ®Google Scholar
• Lu Y , ChenY, GemeinhartRA, WuW, LiT. Developing nanocrystals for cancer treatment. Nanomedicine (Lond.)10(16), 2537–2552 (2015).
   PubMed Web of Science ®Google Scholar